Mori M, Kovalenko L, Malancona S, Saladini F, De Forni D, Pires M, Humbert N, Real E, Botzanowski T, Cianférani S, Giannini A, Dasso Lang MC, Cugia G, Poddesu B, Lori F, Zazzi M, Harper S, Summa V, Mely Y, Botta M. Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains. ACS Chem Biol. 2018 Jan 19;13(1):253-266. doi: 10.1021/acschembio.7b00907. 


Tőke ER, Lőrincz O, Csiszovszki Z, Somogyi E,Felföldi G, Molnár L, Szipőcs R, Kolonics A, Malissen B, Lori F, Trocio J, Bakare N, Horkay F, Romani N, Tripp  CH, Stoitzner P, Lisziewicz J, Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes Gene Therapy 2014 Apr 3. doi:10.1038/gt.2014.29.

De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lőrincz O, Sanders NN: Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One. 2014 Feb 4;9(2):e87837. doi: 10.1371/journal.pone.0087837.


Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Mailliard RB, Li XD, Martinez AI, Tenorio AR, Lori F, Lisziewicz J, Yesmin S, Rinaldo CR, Pollard RB. Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):351-9. doi: 10.1097/QAI.0b013e3182a99590. PubMed PMID: 24169120.

Somogyi E, Lisziewicz J. HIV vaccine to induce cytotoxic T cells recognizing conserved HIV-1/2-epitopes derived from the most frequent HLA types of the human population. Immunotherapy. 2013 Aug;5(8):825-8. doi: 10.2217/imt.13.79. PubMed PMID: 23902551.

Garaczi E, Szabó K, Francziszti L, Csiszovszki Z, Lőrincz O, Tőke ER, Molnár L, Bitai T, Jánossy T, Bata-Csörgő Z, Kemény L, Lisziewicz J. DermAll nanomedicine for allergen-specific immunotherapy. Nanomedicine. 2013 Nov;9(8):1245-54. doi: 10.1016/j.nano.2013.05.011. Epub 2013 Jun 6. PubMed PMID: 23747740.


Lisziewicz J, Tőke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine. 2013 Jan;9(1):28-38. doi: 10.1016/j.nano.2012.05.012. Epub 2012 May 30. Review. PubMed PMID: 22659241

Lisziewicz J, Bakare N, Calarota SA, Bánhegyi D, Szlávik J, Ujhelyi E, Tőke ER, Molnár L, Lisziewicz Z, Autran B, Lori F. Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One. 2012;7(5):e35416. doi: 10.1371/journal.pone.0035416. Epub 2012 May 9. PubMed PMID: 22590502; PubMed Central PMCID: PMC3348904.

Lori F, De Forni D, Katabira E, Baev D, Maserati R, Calarota SA, Cahn P, Testori M, Rakhmanova A, Stevens MR. VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics. PLoS One. 2012;7(10):e47485. doi: 10.1371/journal.pone.0047485, 2012


Somogyi E, Xu J, Gudics A, Tóth J, Kovács AL, Lori F, Lisziewicz J. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP(+)) mimicking naturally occurring HIV. Vaccine 2011. 29: 744-753


Toke ER, Lorincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine productsInt J Pharm. 2010 Jun 15;392(1-2):261-7. doi: 10.1016/j.ijpharm.2010.03.048. Epub 2010 Mar 25. PubMed PMID: 20347027.

De Forni, D., Stevens, MR., and Lori, F. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in human immunodeficiency virus/acquired immunodeficiency syndrome. British Journal of Pharmacology 161(4):830-43, 2010.


Lisziewicz J. Conference scene--active immunotherapeutics forum: meeting highlights. Immunotherapy. 2009 Sep;1(5):743-8. doi: 10.2217/imt.09.52. PubMed PMID: 20636019


Lori F. Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation. Curr Opin HIV AIDS. 2008 Mar;3(2):99-103

Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine. 2008 Sep 19;26(40):5188-95

Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol. 2008 May 1;180(9):5907-15

Shepard  BD, De Forni D., McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD. Beneficial Effect of TRAIL on HIV Burden, without Detectable Immune Consequences. PLoS One 3:1-7, 2008.

Lori F. Fas, IL-7, and T cells: live and let die. Blood 112:930-931, 2008.


Lori F, Calarota SA, Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem. 2007;14(18):1911-9

Foli A, Maiocchi MA, Lisziewicz J, Lori F. A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. J Infect Dis. 2007 Nov 1;196(9):1409-15.

Calarota SA , Weiner DB,  Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine. 2007 Apr 20;25(16):3070-4

Lori F, Foli A, Kelly LM, Lisziewicz J. ViroStatics: a new class of anti-HIV drugs. Curr Med Chem. 2007;14(2):233-41

Lori F, Foli A, Lisziewicz J. Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options. Curr Opin HIV AIDS. 2007 Jan;2(1):14-20

Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol. 2006 Nov;28(3):231-8

Lisziewicz J, Kelly L, Lori F. Topical DermaVir vaccine targeting dendritic cells. Curr Drug Deliv. 2006 Jan;3(1):83-8

Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N, Pollard RB, Lisziewicz J. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. AIDS. 2005 Jul 22;19(11):1173-81

Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses. 2005 Apr;21(4):263-72

Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J. DermaVir, a novel HIV immunisation technology. Vaccine. 2005 Mar 18;23(17-18):2030-4

Lova L, Groff A, Ravot E, Comolli G, Xu J, Whitman L, Lewis M, Foli A, Lisziewicz J, Lori F. Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. AIDS. 2005 Jan 28;19(2):137-44

Lisziewicz J, Trocio J, Whitman L, Varga G, Xu J, Bakare N, Erbacher P, Fox C, Woodward R, Markham P, Arya S, Behr JP, Lori F. DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol. 2005 Jan;124(1):160-9

Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F. Control of viral rebound through therapeutic immunization with DermaVir. AIDS. 2005 Jan 3;19(1):35-43

Lisziewicz J, Foli A, Wainberg M, Lori F.  Hydroxyurea in the treatment of HIV infection: clinical efficacy and  safety concerns.Drug Saf. 2003;26(9):605-24

Kelly LM, Lisziewicz J, Lori F. "Virostatics" as a potential new class of HIV drugs. Curr Pharm Des. 2004;10(32):4103-20

Lori F, Kelly LM, Lisziewicz J.  APC-targeted immunization for the treatment of HIV-1 Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S189-98

Lori F, Kelly LM, Foli A, Lisziewicz J. Safety of hydroxyurea in the treatment of HIV infection. Expert Opin Drug Saf 2004 Jul; 3(4): 279-88

Lori F, Maserati R, Lisziewicz J, Minoli L.  Immune reconstitution and control of HIV. HIV Clin Trials. 2004 May-Jun;5(3):170-82

Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatmente interruptions. Antivir Ther. 2004 Feb;9(1):123-32

Lisziewicz J, Lori F.  2nd International Symposium on Molecular Diagnostics and Skin Gene Therapy. Expert Opin Biol Ther. 2003 Jul;3(4):683-7

Lori F, Kelly LM, Lisziewicz J.  Immunological approaches for HIV therapy. Curr Drug Targets Infect Disord. 2003 Jun;3(2):171-8

Xu J, Lori F, Lisziewicz J.  Vaccinia assay for the rapid detection offunctional HIV-specific CD8+ cytotoxic T lymphocytes. J Immunol Methods. 2003 May 1;276(1-2):45-57

Lisziewicz J, Bakare N, Lori F. Therapautic vaccination for future management of HIV/AIDS.Vaccine. 2003 Jan 30;21(7-8):620-3

Lisziewicz J, Wainberg M, Lori F:  Is There  a Role for Hydroxyurea in the Treatment of HIV Infection?  Drug Safety.  26(9): 605-24, 2003

Lori F, Guallini P, Galluzzi L, Lisziewicz J. Gene therapy approoaches to HIV infection . Am J Pharmacogenomics. 2002;2(4):245-52

Xu J, Whitman L, Lori F, Lisziewicz J. Quantification of HIV-specific CD8 T cells by in vitro stimulation with inactivated viral particles.  AIDS. 2002 Sep 27;16(14):1849-57

Lori F, Foli A, Lisziewicz J. Structured treatment  interruptions  as a potential alternative therapeutic regimen for HIV-infected patiens: a review ofrecent clinical data and future prospects.  J Antimicrob Chemother. 2002 Aug;50(2):155-60

Foli A, Seminari E, Ravot E, Lisziewicz J, Lori F. Role of hydroyurea during structured treatment interruptions.  J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):64-8

Lori F, Foli A, Maserati R, Seminari E, Xu J, Whitman L, Ravot E, Alberici F, Lopalco L, Lisziewicz J.  Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous  T cell responses. HIV Clin Trials. 2002 Mar-Apr;3(2):115-24

Ravot E, Comolli G, Lori F, Lisziewicz J.  High efficiency lentiviral gene delivery in non -dividing cells by deoxynucleoside treatment. J Gene Med. 2002 Mar-Apr;4(2):161-9

Lisziewicz J, Lori F. Structured treatment interruptions in HIV/AIDS therapy. Microbes Infect. 2002 Feb;4(2):207-14

Xu J, Whitman L, Lori F, Lisziewicz J. Methods of using interleukin 2 to enhance HIV-specific immune responses. AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):289-93

Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. J Virol. 2002 Mar;76(5):2274-8


Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA. 2001 Dec 19;286(23):2981-7

Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J, Lori F. Direct analysis of mithocondrial toxicity of antiretroviral drugs. AIDS. 2001 Sep 7;15(13):1687-94

Lisziewicz J, Gabrilovich DI, Varga G, Xu J, Greenberg PD, Arya SK, Bosch M, Behr JP, Lori F. Induction of potent human immunodeficiency virus type 1-specific T-cell restricted  immunity by genetically modified dendrtitic cells.  J Virol. 2001 Aug;75(16):7621-8

Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J. Control of SIV rebound through structured treatment interruptions during early infection.Science. 2000 Nov 24;290(5496):1591-3

Lori F, Lisziewicz J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7

Ravot E, Tambussi G, Jessen H, Tinelli C, Lazzarin A, Lisziewicz J, Lori F.Effects of hydroxyurea on T cell count changes during primary HIV infection. AIDS. 2000 Mar 31;14(5):6 19-22

Lisziewicz J, Zeng G, Gratas C, Weinstein JN, Lori F. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule.  Hum Gene Ther. 2000 Apr 10;11(6):807-15

Lori F, Lisziewicz J. Role of immune modulation in primary HIV infection. J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):45-8

Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV-1 infection.Lancet. 2000 Jan 22;355(9200):287-8

Lori F, Lisziewicz J. Hydroxyurea: overview of clinical data and antiretroviral and  immunomodulatory effects. Antivir Ther. 1999;4 Suppl 3:101-8

Ravot E, Lisziewicz J, Lori F. New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.Drugs. 1999 Dec;58(6):953-63

Lori F, Lisziewicz J. Targeting HIV reservoirs and reconstituting the immune system. Second annual meeting Research Institute for Genetic and Human Therapy April 18-19, 1999 Washington, DC. AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1597-617

Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B, Siliciano RF, Lisziewicz J. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.  J Infect Dis. 1999 Dec;180(6):1827-32

Lori F, Lisziewicz J. Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea.  J Biol Regul Homeost Agents. 1999 Jul-Sep;13(3):176-80

Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B, Lisziewicz J.  Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1333-8

Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, Lori F. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999 May 27;340(21):1683-4

Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).  AIDS Res Hum Retroviruses. 1999 May 1;15(7):619-24

Lori F, Lisziewicz J. Cellular factors: targets for the treatment of HIV infection. Antivir Ther. 1998;3 Suppl 4:81-92

Lori F, Lisziewicz J.  Hydroxyurea: mechanisms of HIV-1 inhibition. Antivir Ther. 1998;3 Suppl 4:25-33

Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet. 1998 Jul 18;352(9123):199-200

Foli A, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, Lori F. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine. AIDS. 1998 Jun 18;12(9):1113-4

Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC, Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses. 1997 Nov 1;13(16):1403-9

De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis. 1997 Oct;176(4):899-903

Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA. 1997 May 14;277(18):1437-8
Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewicz J. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. Antivir Ther. 1997 Jan;2(1):31-8


Lisziewicz J, Sun D, Gallo RC, Ensoli B, Lori F. Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines. Hum Gene Ther. 1996 Dec 1;7(18):2209-16

Lisziewicz J. TAR decoys and trans-dominant gag mutant for HIV-1 gene therapy. Antibiot Chemother. 1996;48:192-7

*  At least one author of each publication was a RIGHT researcher or employed by a RIGHT spin off company.